NTHI
Neonc Technologies Holdings, Inc. · Healthcare
5.66
1.39%(-0.08)
Market OpenLast Updated: — ET
52W L: $3.2052W H: $12.99
$5.60
CHG-3.76 (-40.18%)
H$10.14
L$5.36
VOL588K
NTHI (1h)
Neonc Technologies Holdings, Inc. · Healthcare
Neonc Technologies Holdings, Inc. (NASDAQ: NTHI - Get Free Report) President Amir Heshmatpour bought 5,000 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was acquired at an average price of $6.32 per share, for a total transaction of $31,600.00. Following the acquisition, the president directly owned 3,017,000 shares in
CALABASAS, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced financial results for the quarter and year ended December 31, 2025, and provided an update on recent operational achievements and upcoming milestones.
CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company's accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations.
Dallas, Texas--(Newsfile Corp. - March 12, 2026) - NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI): Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). NeOnc Technologies is a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain.
Neonc Technologies Holdings, Inc. (NASDAQ: NTHI - Get Free Report) dropped 0.1% during trading on Wednesday. The stock traded as low as $9.30 and last traded at $9.41. Approximately 13,768 shares traded hands during trading, a decline of 76% from the average daily volume of 56,570 shares. The stock had previously closed at $9.42. Wall
CALABASAS, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced data from the dose-escalation portion of its Phase 1/2 clinical trial for NEO212, the Company's novel oral bio-conjugated therapy and will host a conference call to discuss the data today at 9:00am ET.
Heshmatpour Amir F
director, 10 percent owner, officer: President
6,000 SH @ $6.51
2025-11-24
Heshmatpour Amir F
director, 10 percent owner, officer: President
4,000 SH @ $6.50
2025-11-21
Heshmatpour Amir F
director, 10 percent owner, officer: President
20,000 SH @ $5.98
2025-11-21
CHIANG MING-FU (ALAN)
director
0 SH @ $0.00
2025-11-12
CHIANG MING-FU (ALAN)
director
0 SH @ $0.00
2025-11-12
CHIANG MING-FU (ALAN)
director
0 SH @ $0.00
2025-11-12
CHIANG MING-FU (ALAN)
director
0 SH @ $0.00
2025-11-12
CHIANG MING-FU (ALAN)
director
0 SH @ $0.00
2025-11-12